UnitedHealth (UNH)
The desk's stance
On our research list, not on the slate.
What the company does
The largest payer in America — UnitedHealthcare commercial/Medicare plans plus Optum PBM and physician networks. Directs over $450B in healthcare spend and dictates prior-authorization barriers for GLP-1 coverage.
In short: Integrated health benefits and services. Category: Mega-cap Managed Care Services. Sector: Healthcare, Healthcare Plans.
G-Street Value and Score
G-Street Value: $376.30, computed Oct 18, 2026 (confidence: medium).
How we got there: 50% analyst leg $407.02 (2 analyst targets, credibility- and freshness-weighted, after 8% optimism discount) + 50% GainStreet factor value $345.58 (14.88× fwd EPS anchored to healthcare multiples). 3 analyst targets have no linked source and are shown but not counted.
G-Street Score: 40 out of 100 (Weak).
- Top-line growth & guidance: 7 of 32
- Margin power: 3 of 15
- Revenue visibility & quality: 3 of 11
- Profitability & balance sheet: 16 of 24
- Capital allocation & governance: 5 of 6
- Valuation, sentiment & momentum: 6 of 12
Our current thesis
Updated Oct 14, 2026
The thesis
- Underwriting discipline and medical loss ratio recovery expand operating margins despite volume pruning.
- Optum services engine generates robust cash flow, underpinning $26.5B in trailing free cash flow.
- Valuation at 17.1x forward earnings offers a defensive cushion below long-term healthcare multiples.
Risks
- Star Rating downgrades and Medicaid rate adjustments threaten Medicare reimbursement bonuses into 2027.
- Flattish sequential revenue trajectory confirms top-line deceleration caused by deliberate risk-bearing member exits.
- Persistent legislative and antitrust scrutiny pressures Optum Rx pharmacy benefit manager pricing models.
What we're watching
- Delivery against the raised fiscal 2026 adjusted EPS guidance floor of $20.50.
- Sustained breakout confirmation above $395 toward the next technical resistance near $415.
- CMS 2028 preliminary rate announcements and resolution of 2027 Star Rating appeals.
Latest
UNH rallied 4.7% to $395.62 following Q3 2026 results where adjusted EPS of $4.69 beat the $4.14 consensus, prompting management to raise full-year guidance to at least $20.50. Medical loss ratio improved 160 bps to 88.4% and Optum operating profit rebounded, successfully offsetting deliberate membership pruning that shed 935,000 Medicare Advantage lives. Trading at 17.1x forward earnings, the stock has broken above near-term resistance and is testing overhead supply toward $410.
Key numbers
As of Oct 16, 2026: market cap $360.3B · revenue growth -0.4% year over year · gross margin 20.0% · net margin 3.5% · forward P/E 17.3 · next earnings Jan 12, 2027.
Analyst price targets
Published analyst targets we could trace to a named source.
- UBS, Buy: $490 target (October 2026). Source: beinsure.com
- TD Cowen, Hold: $402 target (October 2026). Source: beinsure.com
On the Gainz Lab maps
Who it does business with
- UnitedHealth competes with CVS Health (Caremark) — Managed-care rivals. Optum vs Caremark: two vertically integrated healthcare giants fighting over employer contracts, PBM rebates, and specialty pharmacy margins.
- UnitedHealth supplies The Patient — The coverage gate. Commercial plan designs, deductibles, and prior authorizations determine which patients actually get their GLP-1 prescriptions filled.